Redeye shares its preview of Physitrack’s Q3 2026 results ahead of the report on 20 October. On the numbers, we expect steady topline growth and a sequential uptick in ARR, offset by YoY margin compression as the North American cost base builds. Beyond the figures, we expect the narrative to centre on EMR (Electronic Medical Records), launched on 28 September and positioned as Physitrack’s next growth avenue alongside RTM.
LÄS MER
